Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood

Angiogenesis

Volumn 4, Issue 2, 2001, Pages 123-131

  Reusch, Petra ^a   Barleon, Bernhard ^b   Weindel, Karin ^a   Martiny Baron, Georg ^a   Gödde, Astrid ^a   Siemeister, Gerhard ^c   Marmé, Dieter ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b Receptor Ligand Technologies GmbH   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; Angiopoietin; Shedding; Soluble receptor; TIE 2

Indexed keywords

ANGIOPOIETIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; TYROSINE KINASE RECEPTOR;

ANGIOGENESIS; ARTICLE; BLOOD SAMPLING; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; BASE SEQUENCE; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PRECIPITIN TESTS; PROTO-ONCOGENE PROTEINS; RECEPTOR, TIE-2; TETRADECANOYLPHORBOL ACETATE;

EID: 0035678581     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012226627813     Document Type: Article

References (42)

1. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
2. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
3. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
4. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue
5. Blood vessel formation: What is its molecular basis?
6. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
7. Vascular endothelial growth factor (VEGF) and its receptors
8. VEGFs, receptors and angiogenesis
9. The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors
10. Molecular cloning and characterization of mouse tie and tek receptor tyrosine kinase genes and their expression in hematopoietic stem cells
11. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans
12. Tie2 receptor expression and phosphorylation in cultured cells and mouse tissues
13. Signaling vascular morphogenesis and maintenance
14. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
15. Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system
16. Vascularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development
17. Expression and function of murine receptor tyrosine kinases, Tie and TEK, in hematopoietic stem cells
18. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo
19. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
20. Potential roles of metalloprotease mediated ectodomain cleavage in signaling by the endothelial receptor tyrosine kinase Tie-1
21. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation
22. Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway
23. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the VEGF receptor FLT-1
24. Soluble receptors for cytokines and growth factors: Generation and biological function
25. Soluble cytokine receptors
26. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
27. Regulation of tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble tie
28. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains
29. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
30. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA
31. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids
32. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors
33. Evidence for heterotypic interaction between the receptor tyrosine kinase TIE-1 and TIE-2
34. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system
35. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells
36. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2
37. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer
38. Plasma urokinase receptor levels in patients with colorectal cancer: Relationship to prognosis
39. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients
40. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
41. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: Correlation with clinicopathological factors and tumor markers
42. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy